🟢 Generate Biomedicines up 5% in pre-market ahead of lock-up expiration and upcoming clinical data

Generate Biomedicines is trading 5.25% up at $21.45, driven by anticipation of its August 26 post-IPO lock-up expiration and excitement for its upcoming September 8 Phase 1b clinical data for GB-0895. - Shares rose 15.01% to $20.38 on August 25, extending significant gains as investors positioned ahead. - The lock-up expiration allows insiders and early investors to sell previously restricted shares. - The company is also set to present Phase 1b data for its lead respiratory drug GB-0895 at the European Respiratory Society Congress on September 8.